



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Lin, J;Finkelstein, DI;Anderson, AJ;Lee, PY;Bui, BV;Wijeratne, T;Alty, JE;Nguyen, CTO

Title:

Keeping an eye on Parkinson's disease: color vision and outer retinal thickness as simple and non-invasive biomarkers

Date:

2025

Citation:

Lin, J., Finkelstein, D. I., Anderson, A. J., Lee, P. Y., Bui, B. V., Wijeratne, T., Alty, J. E. & Nguyen, C. T. O. (2025). Keeping an eye on Parkinson's disease: color vision and outer retinal thickness as simple and non-invasive biomarkers. *Journal of Neurology*, 272 (5), <https://doi.org/10.1007/s00415-025-13080-6>.

Persistent Link:

<https://hdl.handle.net/11343/360508>

License:

CC BY



Keeping an eye on Parkinson's disease: color vision and outer retinal thickness as simple and non-invasive biomarkers

Jingjing Lin¹ · David I. Finkelstein² · Andrew J. Anderson¹ · Pei Ying Lee¹ · Bang V. Bui¹ · Tissa Wijeratne³ · Jane E. Alty^{4,5} · Christine T. O. Nguyen¹ 

Received: 24 February 2025 / Revised: 25 March 2025 / Accepted: 28 March 2025 / Published online: 21 April 2025
© The Author(s) 2025

Abstract

Over the last two decades, visual symptoms and retinal changes in Parkinson's disease (PD) have emerged as important biomarkers. Color vision deficiency, which begins in the outer retina, has been increasingly investigated, but a focused review of these papers has not recently been conducted. Similarly, thinning of the outer retina as measured using optical coherence tomography (OCT) holds potential as a screening marker for PD, particularly as these devices are already commonplace in community and hospital settings. Moreover, outer retinal thinning may be more specific for Parkinson's disease as inner retinal changes also occur in more common neurodegenerative diseases like glaucoma and Alzheimer's disease. This review summarizes contemporary evidence on two *outer retina* focused measures, color vision and outer retinal thickness, which can be readily quantified using non-invasive approaches and thus examines their potential as biomarkers for screening, detection, and progression in PD.

Keywords Neurodegenerative disorders · Parkinsonism · Visual impairment · Optical coherence tomography

Introduction

The need for low-cost and scalable biomarkers

Parkinson's disease (PD) is a fast-growing neurodegenerative disorder globally [1], and it is predicted that there will be over 12 million people living with PD (pwPD) worldwide by 2040 [2]. Clinical diagnosis of PD mainly relies on the presence of motor features, such as tremor, bradykinesia,

and muscle rigidity [3]. However, studies have shown that by the time these cardinal symptoms present, substantial and irreversible neuronal loss (up to 70%) has already occurred in the substantia nigra [4, 5]. As such, there is a critical need for tools that help identify PD earlier in the disease course, as well as effectively track progression. Current brain-related biomarkers of PD are either costly (magnetic resonance imaging, positron emission tomography scans) or invasive; for example, the new alpha-synuclein seed amplification assays require cerebrospinal fluid or skin biopsy tests [7–9]. Thus, there remains a need for a scalable biomarker of PD that can be used at a population level, considering the large and escalating number of pwPD [6].

Why should we look into the eyes?

Eye-related biomarkers have garnered interest in PD as visual abnormalities are common non-motor symptoms in the clinically diagnosed stage of PD [10–18]. Although subtle for a patient to notice, they can be readily quantifiable in the clinic. Importantly, there is evidence that they occur up to a decade before PD diagnosis, within the prodromal stage [19]. People with idiopathic rapid eye movement sleep behavior disorder (iRBD) are a prodromal group of great

✉ Jane E. Alty
jane.alty@utas.edu.au

✉ Christine T. O. Nguyen
christine.nguyen@unimelb.edu.au

¹ Department of Optometry and Vision Sciences, The University of Melbourne, Melbourne, VIC, Australia

² Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia

³ Department of Neurology, Sunshine Hospital, Melbourne, VIC, Australia

⁴ Wicking Dementia Research and Education Centre, University of Tasmania, Hobart, TAS, Australia

⁵ Neurology Department, Royal Hobart Hospital, Hobart, Australia

interest as they have a 70–90% risk of developing PD and related neurodegenerative disorders (i.e., dementia with Lewy Bodies, multiple system atrophy) [20–22]. However, iRBD is under-recognized and under-diagnosed in the community, partly related to poor awareness and inaccessible specialist sleep study tests [23, 24], and yet we know that early vision changes have been found in this group, too [25].

The mechanisms underlying visual symptoms in PD are an exciting area of research and include investigation of the two PD hallmarks, namely dopaminergic deficiency [26–28] and misfolded alpha-synuclein in the retina [29–32]. Overall, similarities between the retina and brain in terms of embryology, structure, and PD-related pathology [14, 33, 34] make the retina a logical and promising avenue as a site to search for early PD biomarkers. More specifically, there is a growing literature that the *outer retina* is altered in PD [35]. This includes converging evidence across functional studies, such as color vision which commences in the outer retina [36], electrophysiology which assays outer retinal activity in vivo [37], and retinal imaging studies including optical coherence tomography (OCT) [38–40] and OCT angiography [41–44] which return outer retinal neuronal structure and vascular structure respectively. This review will focus on *color vision and outer retinal OCT* given their greater accessibility and thus potential as implementable biomarkers in PD.

Systematic review of the literature

To date, there is a lack of review papers that focus on the outer retina, and thus, the current manuscript specifically examines two tools that enable assessment of the outer retina, with the potential for widespread clinical implementation: color vision and outer retina OCT changes. We aimed to systematically review the literature to provide a narrative summary of the current understanding of color vision impairment in PD and explore opportunities for outer retina OCT parameters to serve as biomarkers for the detection of PD, including in its prodromal stage as well as its progression.

This narrative review included a literature search conducted in the PubMed database, with a search term of (“Parkinson” [All Fields] OR “rapid eye movement sleep behavior disorder”) AND (“optical coherence tomography” OR “OCT” [All Fields]), as well as (“Parkinson” [All Fields] OR “rapid eye movement sleep behavior disorder”) AND (“color vision” OR “color discrimination” OR “color vision deficiency” [All Fields]). First, research articles with their abstract and result section mentioning any of the outer retinal layers (including outer plexiform layer (OPL), outer nuclear layer (ONL), photoreceptors layer (PRL), and retinal pigment epithelium (RPE)) or color vision information were screened. Second, the full text was reviewed to determine whether color vision and outer retinal OCT

were detailed in the method section for inclusion. Third, the reference articles from all screened studies were checked. Cohen’s *d* Effect Size [45] was calculated to measure the statistical power based on data (numbers of samples, the mean value, and standard deviation of compared parameters) provided in research articles.

Color vision

What exactly is color vision?

Color vision is the ability to distinguish chromatic or “colored” objects [46] and involves both retinal and cortical components of the visual pathway. In the retina, three types of cone photoreceptors are responsible for color vision: S cones, M cones, and L cones, reflecting preferential sensitivity to short, medium, and long wavelengths of light, respectively. Lights with different spectral distributions can produce differences in the relative activation of these three cone classes, with this information then processed through bipolar cells in the middle retina, laterally communicated through amacrine cells, then transmitted to ganglion cells in the innermost retina, and then to the brain. In the brain, both achromatic (luminance) and chromatic (color) signals pass through the lateral geniculate nucleus in the thalamus and onward to the primary visual cortex. Visual information is streamed into three pathways: magnocellular (luminance), parvocellular (red–green), and koniocellular (blue–yellow). Therefore, impairment at any stage in the visual pathway can lead to aberrant color discrimination [46].

Congenital color vision deficiency is relatively common in the population (8% in males and 0.5% in females) and largely occurs on the red–green axis [47]. On the other hand, acquired color vision deficiencies, including those caused by acquired retinal disease and by exposure to environmental/toxins may involve the blue–yellow axis [48].

How is color vision currently assessed?

Common clinical tests of color vision include pseudoisochromatic plates (e.g., Ishihara test, Fig. 1a), hue arrangement tests (e.g., Farnsworth–Munsell 100-Hue test, Fig. 1b), and color matching tests (e.g., anomaloscope, Fig. 1c). Different kinds of tests serve different purposes (i.e., screening or gold standard assessment; congenital versus acquired color vision deficiencies) in clinical practice and research. The anomaloscope is the gold standard color vision test and involves matching a test color with two different colored lights but is mostly utilized for research purposes due to its expense and expertise to operate (Fig. 1c). On the other hand, the Ishihara test is widely used in clinic, especially for screening of congenital red–green color vision defects [49], and requires discerning numbers formed




Fig. 1 Common clinical color vision tests. **a** Ishihara test (24-plate edition 2011, Kanehara Trading Inc., Tokyo, Japan); **b** Farnsworth–Munsell 100-Hue test (FM 100-Hue, X-Rite, Grand Rapids, MI, USA); **c** Anomaloscope test (OT-II, Neitz Instruments Co., Ltd., Tokyo, Japan)

by dots within a field of dots in a different color (Fig. 1a). In the PD research literature, the FM- 100 Hue test is the most commonly used color vision test due to its high accuracy and moderate accessibility. The test involves arranging 85 colored caps in order of hue, with higher error scores indicating worse performance (Fig. 1b). Modern computerized tests of color vision enable tailored assessment of multiple aspects of color vision and with the digital age facilitate the potential for widespread implementation.

Color vision deficiency in Parkinson's disease

As shown in Table 1 and Fig. 2, color vision deficiency has been evaluated in multiple cross-sectional studies of people with untreated PD who are drug-naïve to dopaminergic medications [50, 51], pwPD treated with dopaminergic drugs [35, 52–56], as well as in longitudinal studies of PD [57–59]. Evidence from most studies suggests that deficits in color vision discrimination could differentiate pwPD from age-matched control cohorts, with significantly higher error scores in FM- 100 or Lanthony Desaturated 15-Hue Test (a modified version of the Farnsworth-D15 with lower saturation) in pwPD compared with healthy controls [35, 50, 52–56, 60–62], although one study found no difference [63]. Encouragingly, 83% (10/12) of studies (Fig. 2) identified significantly impaired color vision in PD and exhibited high Cohen's *d* Effect size ranging from ~ -0.6 to 4.9 (including 95%CI) regardless of cohort, age, sex, disease duration, disease severity, treatment, and color vision test settings (e.g., lighting conditions). One study found that 30 pwPD (mean age: 65.6 years old) and 30 age-matched healthy controls could be differentiated with both a specificity and sensitivity of 0.67 using a cut-off FM- 100 total error score of 115.2 [54].

Color vision deficiency in prodromal Parkinson's disease

Postuma and colleagues extended previous work in the PD field and examined color discrimination in prodromal PD;

participants with iRBD [19, 20, 64, 65]. The initial two cross-sectional studies from Postuma et al. [64, 65] demonstrated a significant color vision impairment in an iRBD cohort with the FM- 100 test (57 polysomnography-confirmed RBD vs 30 age- and sex-matched healthy controls, $P < 0.001$). In 2019, they reported data collected from their longitudinal study (154 iRBD participants and 102 healthy controls, 2004–2016) and used a mixed effect model to predict that the first presentation of impaired color vision can occur 12.8 years before iRBD converted to neurodegenerative diseases such as PD, dementia with Lewy bodies, and multiple system atrophy [19]. Furthermore, with a cut-off error score in FM- 100 more than 153, the largest area under the receiver-operating characteristic curve (AUROC) for separating iRBD phenoconverters from controls based on FM- 100 was 0.71 at the year of phenoconversion, with a sensitivity of 0.70 and a specificity of 0.61; FM- 100 testing also gave an AUROC of 0.65 six years prior to phenoconversion, with a sensitivity of 0.56 and a specificity of 0.61. In comparison, quantitative measures of cardinal motor symptoms started 7–11 years prior to formal PD diagnosis [19]. Postuma et al. [20] also conducted an international multi-center study with the largest iRBD cohort to date of 1280 polysomnography-proven participants with a mean age of 66.3 years old (82.5% male), of which 240 participants completed the FM- 100. Importantly, the rate of iRBD participants phenoconverting to PD and related disorders was 69% higher in those with color vision abnormalities (hazard ratio = 1.69, 95% CI 1.01–2.78).

Interestingly, previous iRBD studies (Table 1) presented similar findings to PD research, as most studies (4/5) showed that iRBD participants had a significant increase in FM- 100 scores compared to healthy controls, with one relatively smaller study (21 iRBD participants vs 21 healthy controls) reporting no change and details regarding the experimental procedure were lacking (i.e., lighting conditions). The Cohen's *d* Effect size ranged from -0.53 – 7.65 (including 95%CI), and the mean value was high at 4.1 for Kim et al.'s study [60] and 6.7 for one of the studies from Postuma et al. [64] (Fig. 2). Of note, all participants from both studies had a

Table 1 Color vision deficiency among people with PD and iRBD

Paper	Numbers of participants		Mean age (years)		Mean Hoehn and Yahr scale	Mean Disease duration (year)	Levodopa therapy (yes/no)	Color vision test	Findings (total error score (TES), AU, Mean \pm SD)		
	PD (iRBD)	HC	PD (iRBD)	HC					PD (iRBD)	HC	P value
Color vision deficiency in PD											
Tran et al. (2024) [35]	16	19	61	57	–	5.0	Yes	FM- 100	123.5 \pm 73.4	52.7 \pm 45.3	< 0.01
Kim et al. (2024) [60]	43	32	68.8	71.1	–	6.0	–	FM- 100	225.9 \pm 11.9	175.2 \pm 13.6	0.018
Li et al. (2019) [66]	52	79	64.2	66.7	1.7	3.7	–	FM- 100	149.2 \pm 63.5 (N = 46)	90.8 \pm 43.6 (N = 69)	< 0.05
Brandt et al. (2018) [56]	30	34	70	60	1.8	6.0	Yes	FM- 100	327.0 \pm 200.0	18.0 \pm 9.0 (N = 31)	0.0001
Satue et al. (2017) [59]	40	–	74.6	–	2.9	18.4	Treat-free: 9%	Farnsworth-D15 and Lanthony-D15	Over 5-year, only Lanthony color confusion Index increased from 1.7 \pm 0.6 to 2.2 \pm 0.5 (P = 0.016)		
Sun et al. (2014) [61]	45	50	65.4	65.5	2.2	8.7	Yes	FM- 100	135.8 \pm 84.8	84.3 \pm 41.7	0.0001
Oh et al. (2011) [53]	54	34	69.0	65.4	1.8	4.3	Yes	FM- 100	182.6 \pm 96.3	82.0 \pm 45.6	0.001
Diederich et al. (2010) [54]	30	30	65.6	67.7	–	2.2	Yes	FM- 100	144.4 \pm 59.8	86.5 \pm 40.8	< 0.001
Kertelge et al. (2010) [67]	100	110	63.7	58.7	2.5	8.4	–	FM- 100	134.8 \pm 92.8 (N = 98) [*]	97.2 \pm 61.1 (N = 109) [*]	0.005
Silva et al. (2005) [68]	30	32	61.1	57.9	1.9	4.6	Treat-free: 33%	Computer-controlled test	PD participants showed impaired color vision in the red–green axis (both P < 0.01), and a trend that did not reach significance in the blue–yellow axis (P = 0.0591)		
Diederich et al. (2002) [58]	28	–	65.2	–	–	13.5	Yes	FM- 100 and Lanthony-D15	Over 19.8 \pm 2.8 months, TES in FM- 100 increased from 99.1 \pm 76.6 to 126.5 \pm 103.5 (P = 0.02), while TES in Lanthony-D15 increased from 7.0 \pm 9.3 to 6.4 \pm 11.4 (P = 0.38)		
Muller et al. (2002) [57]	18	–	61.4	–	–	–	Yes	FM- 100	Over 3 years, TES increased from 69.7 \pm 32.2 to 134.1 \pm 85 (P = 0.002)		
Veselá et al. (2001) [63]	14	20	55.4	51.2	1.4	2.3	No	FM- 100	First trial: 49.1 \pm 37 Second trial: 36.1 \pm 31	37.9 \pm 25 31.4 \pm 25	< 0.528 < 0.806
Pieri et al. (2000) [62]	21	30	69.9	67.9	2.6	9.6	Yes	Lanthony-D15	6.4 \pm 8.9	2.9 \pm 4.8	0.18
Muller et al. (1999) [50]	30	30	58.7	57.6	2.0	–	No	FM- 100	121.7 \pm 70	37.7 \pm 42	0.0001
Haug et al. (1995) [55]	26	17	64.5	62.6	2.2	–	Yes	Lanthony-D15	79.4 \pm 50.6	18.4 \pm 9.6	0.0001
									10.5 \pm 7.3	4.2 \pm 4.1	0.001


Table 1 (continued)

Paper	Numbers of participants		Mean age (years)		Mean Hoehn and Yahr scale	Mean Disease duration (year)	Levodopa therapy (yes/no)	Color vision test	Findings (total error score (TES), AU, Mean ±SD)		P value	
	PD (iRBD)	HC	PD (iRBD)	HC					PD (iRBD)	HC		
Buttner et al. (1995) [51]	16	16	58.0	57.8	1.5	1.6	No	FM- 100	64.6 ±24.0	16.0 ±6.8	0.0001	
Price et al. (1992) [52]	35	26	63	60	2.7	-	Yes	FM- 100	238.3	73.1	0.0001	
Color vision deficiency in iRBD												
Kim et al. (2024) [60]	28	32	73.9	71.1	-	8.4	-	FM- 100	232.6 ±14.8	175.2 ±13.6	0.016	
Dušek et al. (2019) [69]	74	39	67.5	65.2	-	6.5	-	FM- 100	102.3 ±78.3	52.4 ±34.2	< 0.0001	
Li et al. (2019) [66]	83	79	67.9	66.7	-	7.3	-	FM- 100	125.6 ±56.5 (N=73)	90.8 ±43.6 (N=69)	< 0.05	
Ehringer et al. (2016) [70]	21	21	67.4	67.6	-	5.9	-	FM- 100	127.4 ±63	120.5 ±78.9	0.76	
Postuma et al. (2009) [64]	68	36	68.0	65.8	-	9.3	-	FM- 100	174.6 ±12.5 (N=57)*	94.5 ±11.6 (N=30)*	< 0.001	

PD Parkinson’s disease; HC Healthy controls; FM- 100 Farnsworth-Munsell 100-Hue test; Farnsworth-D15 Farnsworth–Munsell Desaturated 15-Hue Test (a simplified version of FM- 100); Lanthony-D15 Lanthony Desaturated 15-Hue Test (a modified version of the Farnsworth-D15 with lower saturation); AU Arbitrary Units; SD standard deviation; iRBD idiopathic rapid eye movement sleep behavior disorder

*Exact number for participants who performed the FM- 100

Fig. 2 Forest plot showing Cohen's d effect size (95% CI) on color vision discrimination tests. Each study is represented by a dot (mean Cohen's d) with error bars (95% CI). Positive values suggest higher error scores in the PD (or iRBD) group compared to healthy controls. Asterisks (*) indicate significant differences between groups; #1 and #2 represent the first and the second FM-100 test, respectively; CI, confidence interval; PD, Parkinson's disease; iRBD, idiopathic rapid eye movement sleep behavior disorder; FM-100, Farnsworth-Munsell 100-Hue test; Lanthony-D15, Lanthony Desaturated 15-Hue Test



gold standard (polysomnography-confirmed) of their iRBD. To avoid overlap in participants, the study selected from Postuma's team was the latest and largest iRBD color vision cross-sectional manuscript. Whether the trend for greater effect size in studies that examine polysomnography-confirmed iRBD compared with studies that test diagnosed PD cases is a reflection of only a subset of pwPD also having iRBD; whether people with iRBD and color vision dysfunction are more likely to convert to other non-PD degenerative disorders (such as dementia with Lewy bodies, and multiple system atrophy) requires further investigation [19].

The underlying pathology of color vision loss in Parkinson's disease

Previous studies have suggested that color vision loss in PD is due to dopamine deficiency affecting the visual system potentially at retinal and cortical sites. Indirect evidence provides support for this idea, with two studies reporting that levodopa therapy could improve color vision [61, 71]. This proposed pathological mechanism aligns with the loss of dopaminergic cells in the substantia nigra [72], as well as decreased dopamine levels [26] and impaired dopaminergic cell function [28] in the retina [27]. In the human retina, dopaminergic cells are mainly amacrine cells [28], the impairment of which can alter signal processing in the visual pathway [73]. Interestingly, the dopaminergic subclass of amacrine cells is the only amacrine cells that have processes that extend to the outer retina [74]. In a previous study by our group [35], pwPD demonstrated greater color vision impairment on FM-100, decreased outer retinal photoreceptor function on electrophysiology, and degeneration of outer retinal

photoreceptor cell nuclei measured as a thinner retinal ONL on OCT scans compared with age-matched healthy controls. Given that the macula ONL consists largely of cones [75], these data identify a potential association with the observed color vision loss.

In 1995, Haug et al. [55] found significantly increased thresholds responding to stimuli on the blue–yellow compared to the red–green axis in PD participants and speculated that the more vulnerable S cones compared to M cones and L cones in the retina contributed to the result. Sun et al. [61] reported similar findings. However, some researchers failed to detect differences in the blue–yellow axis in PD [58, 63, 76]. In contrast to Haug and co-workers, Silva et al. [68] performed detailed eye exams in the participant inclusion to mitigate the influence of confounding factors such as age-related ocular changes and found that deficits in the blue–yellow axis were not as marked as deficits in the red–green axis, which were considered distinct from age and as disease-specific. Nevertheless, a former study conducted by Regan et al. [77] used the same color vision test but detected no difference in color vision on any axis between pwPD and healthy controls. The lack of differences might be due to these participants with red–green color deficiencies being pre-excluded with the Ishihara test, an effort to exclude congenital color vision loss but may have also excluded PD-related color deficiencies.

Collectively, the exact contributions of retinal and cortical components, as well as retinal cells and visual pathways to color vision deficit in PD require further investigation. Future studies are needed to determine whether there is a consistent pattern of color vision dysfunction in pwPD and whether this varies across different subtypes of PD and alters with disease course.

Linking color vision to the disease stage of Parkinson's disease

Previous literature has examined the severity of PD and how it is related to color vision deficiency. Currently, both the Hoehn and Yahr stage [78] and the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) [79] are used to assess the severity of PD, but there is variation in the consistency of rating across clinics [80]. The Hoehn and Yahr staging is a categorical scale that mostly focuses on motor symptoms, while the MDS-UPDRS measures self-reported information and examination results in 4 separate parts, including "non-motor experiences of daily living", "motor experiences of daily living", "motor examination", and "motor complications". However, neither of these scales includes items directly related to assessing color vision impairment, or the relationship between color vision deficiency and the severity of PD. A number of studies have reported that higher Hoehn and Yahr stage [53, 66] or higher whole UPDRS [53, 57, 58, 81] are associated with worse performance in FM-100. It is speculated that the deterioration in color vision is correlated with other visual deficits, such as reduced contrast sensitivity (an indicator of how well people can detect objects within a background) [62], stereopsis [61] and oculomotor [81] impairment (which are driven by how well the two eyes work together), and even visual hallucinations [82], that can indirectly impact the motor experiences in daily life [57, 58]. Conversely, other researchers have demonstrated no association between FM-100 error score and PD stage [51, 60, 83, 84]. Interestingly, Muller et al. [84] found that motor impairment tested by peg insertion abilities was significantly associated with FM-100 error score, while no association was found between the total UPDRS score and FM-100 error score. Whether color vision discrimination could be used to stratify different stages of PD needs to be further investigated with larger cohorts and longitudinal observation.

Related disturbing factors in color vision assessment of Parkinson's disease

Age is considered the most important confounder of potential ocular PD biomarkers, as healthy aging can cause changes in the eye and increase disease risk [34, 36, 85]. Performance on color vision tests, especially on the blue–yellow axis, can also be affected by aging, which arises primarily due to lenticular senescence and preferentially reduces the transmission of blue light to the retina [86]. However, age-related deficits in color discrimination have not been consistently reported, as some researchers have found a positive significant correlation between color discrimination thresholds and age [61, 77], which contradicts others that failed to find significant correlations [62,

81]. In previous cross-sectional PD studies, most researchers have pre-excluded participants with age-related ophthalmologic changes (such as cataracts, glaucoma, and age-related maculopathy) to mitigate the influence of age in the eye [51, 60, 83, 84].

Another critical issue raised by researchers employing color vision tests in pwPD is the testing method. Despite the FM-100 exhibiting high test–retest errors [87], it also requires certain executive ability when participants arrange small colored caps. Therefore, some researchers have suggested that altered motor capacity [81, 84] in pwPD could influence FM-100 results, and thus, this test might not precisely reflect color vision discrimination deficits in pwPD [64, 68, 77, 81, 83, 84]. Additionally, impairment of saccadic eye movement [88] and convergence ability [89] in pwPD might also contribute to increased errors. Moreover, the performance of FM-100 can be significantly influenced by cognitive dysfunction [64, 83]. PwPD with cognitive decline may perform worse with the FM-100 because this test also requires executive abilities such as working memory and planning, which can be impaired in pwPD [90].

Consequently, there has been an interest in pseudoisochromatic tests (such as the Ishihara test, Fig. 1a), which are generally easier to understand and perform in clinical practice compared with color cap arrangement tests (Fig. 1b) [91]. However, results with pseudoisochromatic tests have been variable. Kupersmith et al. [92] administered the Ishihara test to 30 PD participants with a mean age of 52 years and found no color abnormalities, which was consistent with the previous results in similar sample sizes of PD participants (from 19 to 30) [58, 93, 94]. In contrast, Suciú et al. [95] performed the Ishihara test and detected an abnormality rate of 33% (10/30) in pwPD with a mean age of 68 years old. Additionally, Bradvica et al. [96] recruited 59 participants and revealed a high specificity of 88.2% and a sensitivity of 55.9% in distinguishing early pwPD (disease duration within 1 year of diagnosis) from age-matched healthy controls with the Ishihara test. However, it is important to note that positive results with the Ishihara test could also include congenital color vision deficiencies, and this test lacks evaluation of the blue–yellow axis. Particularly focusing on tests for blue–yellow deficits, Birch et al. [76] tested 44 PD participants (mean age was 68.5 years) and 40 age-matched normal controls on a range of clinical plates and color arrangement tests, including the City University Tritan plates, SPP2 (Tritan designs), Lanthony Tritan Album, Sahlgren's Saturation Test, T16 and Adams D15. They showed that only the Adams D15, which was a color arrangement test, reached a high sensitivity of 95% and a specificity of 57.5% [76]. A major limitation of using conventional plate tests, compared to arrangement tests, is that these tests produce categorical pass/fail results instead of quantitative variables, and as such, small changes can be missed which may

contribute to the differences seen in the different tritan tests employed by Birch et al. [76].

Some researchers have recommended using computerized color vision test devices to address the above limitations of FM- 100 [68]. Previous studies have employed customized lab-based examinations, and some variation exists between studies. Haug et al. [55, 97] used a computer-controlled system the ‘Moorfield Vision System’ and found a significant elevation of color thresholds along the blue–yellow axis. Others employed a ‘Cambridge Research Systems’ platform and revealed a preferential red–green loss [68], but another group failed to find a significant loss of color vision in either axis using the same platform with different experimental parameters [77]. Current commercially available computerized color vision test devices, such as the Cone Contrast Test [98, 99] and the Colour Assessment and Diagnosis test [100, 101], have not yet been examined in PD, but further research may aid in determining their utility for PD in terms of screening and monitoring.

Previous evidence has repeatedly shown that both PD and prodromal PD (iRBD cohorts) exhibited impaired color vision assessed by the FM- 100 test. However, the FM- 100 is not a common approach in standard clinical eyecare practice [49] and is used predominantly in specialized color vision clinics under specific lighting conditions. Given these challenges with current color vision tests, there would still be utility in the field for a simple-to-administer robust color vision test that could be implemented on a population scale for PD screening.

Outer retinal thickness

Outer retinal OCT: a scalable biomarker

As shown in Fig. 3, the retina is a well-organized tissue with multiple layers, and its structure can be assayed *in vivo* using OCT, a widespread, non-invasive, and rapid method. The macula area of the retina contains a high density of cones, which contribute to color vision and the ability to see fine details. A reduction of retinal layers in thickness or volume quantified using OCT can localize neurodegeneration or the loss of neural tissue to a particular sub-layer of cells. In contrast, the thickening of layers can reflect swelling, gliosis, as well as accumulation of deposits.

OCT is a high-resolution *in vivo* imaging method that allows the assessment of retinal structure in both clinical (including community and hospital) and research settings. OCT employs low-coherence light to measure backscattering properties, which differ between nuclei and dendritic layers of neural tissue in the retina [102, 103]. In the past 20 years, OCT technology has rapidly advanced,

and commercial devices can now reveal retinal structures with high resolution (down to 3 μm [104]), excellent repeatability, and in a matter of seconds due to high scanning speed [105, 106]. Built-in automatic segmentation and analysis algorithms reliably quantify ten individual retinal layers (illustrated in Fig. 3). Common automated analysis outputs focus on the inner retina, as nerve fiber layer thinning is an important indicator of common eye diseases such as glaucoma. Similarly, OCT application in PD has also focused on inner retinal OCT changes in PD [107–112]. However, inner retinal thinning can occur in a range of conditions, including Alzheimer’s disease, multiple sclerosis, and traumatic brain injury. The emergence of imaging and analysis approaches to focus our attention on the outer retina increases the likelihood of improved specificity for PD.

Structural OCT changes in the outer retina of people with Parkinson’s disease

In recent PD studies, OCT has been used to quantify retinal layer thicknesses in pwPD [39]. Inzelberg et al. [113] in 2004 was the first to examine OCT in pwPD and found a significant decrease in retinal nerve fiber layer (RNFL, axons of ganglion cells) thickness in pwPD compared with age-matched controls. Since then, many studies have assessed differences in inner retinal ganglion cell-related layers, including the RNFL, ganglion cell layer, and inner plexiform layer between pwPD and healthy participants [107–112]. A recent meta-analysis [110] of 36 studies found that pwPD demonstrated a significant thinning in inner retinal ganglion cell-related layers (i.e., RNFL, macular ganglion cell complex), as well as overall thickness at the macula (macular volume and macula thickness) compared with age-matched healthy controls. Fewer studies have examined outer retinal changes in pwPD, and a recent review that focuses on these is lacking.

Table 2 summarizes the current outer retinal OCT literature including studies that examine outer retinal changes in a single outer retinal layer and combined outer retinal layers. These are ordered from the most to least recent publications. The more recent papers published 2014–2024 employ the current gold standard three-dimensional OCT scans which evaluate thickness across a wide region of the retina (Table 2A). Older studies utilize a single-line scan reflecting the availability of the technology at the time (2012–2014). Interestingly, none of the older studies employing single horizontal line scans in PD demonstrate a change in the outer retina. In contrast more comprehensive recent studies employing volume scans more consistently report changes. These changes are visualized in Fig. 4, where data from the four commonly reported outer retinal OCT metrics have been expressed as a Cohen’s *d* effect size. More specifically,

the OPL (outer plexiform layer, consisting of photoreceptor dendrites that connect to the downstream bipolar cell dendrites), ONL (outer nuclear layer that represents photoreceptor cell bodies), PRL (photoreceptor layer which includes photoreceptor inner and outer segments), and RPE (retinal pigment epithelium, support cells for outer retinal photoreceptors) are plotted for 3D OCT volume scans. Volume scans were analyzed to return average “thickness” or total “volume”.

Figure 4a shows that in the OPL, some studies demonstrated a positive Cohen’s *d* effect size value and significant thickening (significance indicated by *asterisks*) [117], one returned a negative Cohen’s *d* and significant thinning [123], while others showed no change [35, 104, 114, 116]. Of interest, Chorostecki et al. [121] reported significant OPL volume thickening. The reason for this discrepancy is unclear and is unlikely to be due to the summary metric, as thickness and volume summaries in the same cohort return similar effect sizes [117]. Only one study [25] has examined OPL thickness in iRBD participants and reported a significant thinning.

The other outer retinal layers demonstrated more consistent changes across studies with either a significant thinning or no change seen in the ONL (thinning [35, 114, 116, 117], no change [104, 122, 123]), PRL (thinning [117], no change [35, 123]), and RPE (thinning [104, 117], no change [35, 114, 116, 123]). The effect size for the PRL and RPE ranged between -1.57 and 0.84 (including 95%CI), whereas the effect size for the ONL was larger in some studies, notably -8.0 (95%CI: -9.9 – -7.0) in Chorostecki et al. [121] and -1.1 (95%CI: -1.6 – 0.6) in iRBD participants in Rascuna et al. [25].

In terms of the combined layers represented in Table 2, some studies have reported thinning of the combined ONL and PRL [124], as well as the whole outer retinal layer [115, 120, 127].

Factors influencing variability in OCT findings

A variety of factors may contribute to differences in reported outer retina changes between PD studies. It is possible that pwPD may exhibit a particular spatial distribution of OCT changes, and averaging across a large non-homogenous region may obscure or dilute localized differences. For instance, Mailankody et al. [120] revealed a thinning of the outer retina in two specific areas (the right nasal quadrant at 0.5 mm from the fovea and the right inferior quadrant at 1 mm away from the fovea) in pwPD (60 eyes, 30 participants) compared to age-matched controls [126]. In their longitudinal study [127], the outer retinal thickness in pwPD in the temporal quadrant at 0.5 mm away from the fovea significantly decreased over 3.4 years of observation. On

the other hand, the outer retinas in all individual macular sectors were thinner in 50 PD participants (100 eyes) [115]. Whether the pathology is localized to specific areas, such as the fovea, perifovea, and parafovea, or it manifests as a diffuse pattern remains unclear.

Discrepancies between studies may also arise from differences in age range, disease duration, and severity, making it difficult to compare results between studies. Also, small sample sizes (Table 2), differences in the OCT devices (e.g., swept-source OCT versus spectral-domain OCT) [128, 129], and differences in automatic retinal layer segmentation can further add to variation between studies [37, 38, 122, 125, 126, 130]. Further analyses considering relative outer and inner retinal changes in targeted retinal layers and regions (e.g., foveal, parafoveal, and superior vs inferior retina) in prodromal and established PD are warranted [25].

Segmentation of the outer retina is particularly difficult due to the retinal glial cell processes and the oblique anatomy of the macula. Lujan and colleagues [131, 132] demonstrate that standard OCT scans cause over-estimation of the ONL by $\sim 50\%$ due to obliquely oriented dendritic processes (Henle fiber layer, process of retinal glial cells) masquerading as ONL in these scans. In contrast, off-axis OCT scanning (directional OCT) enables a more accurate assessment of the ONL, OPL, and Henle fiber layers [133–135]. How accurately standard OCT scans are conducted “on-axis” is also not well documented in these studies. This is important for the outer retina as slight variations here can cause large inaccuracies in the ONL. Directional OCT imaging in pwPD or prodromal PD which enables more accurate delineation of the ONL, OPL, and usually, hidden Henle fiber layer would also be helpful for the field.

Considering the thickness changes in the inner retina are easily confounded with other neurodegenerative diseases (e.g., Alzheimer’s disease [136, 137]) and ocular diseases (e.g., glaucoma [138]), outer retinal changes could reveal more disease-specific characteristics in PD. To validate the diagnostic and prognostic potential of thickness parameters in PD, further clinical studies recruiting early stage pwPD or iRBD with longitudinal follow-up observations, as well as investigation of several regions of interest within the retina are warranted.

The underlying pathology of outer retinal alterations in Parkinson’s disease

Though it is hard to draw a definitive conclusion based on the previous findings of outer retinal changes, researchers have proposed potential mechanisms to account for retinal involvement in PD. Increases in thickness or volume have been attributed to a number of mechanisms, such as localized cell swelling associated with the initial stage of cell death [120, 127], a compensatory reaction in response to

a disease-related neurodegeneration [125], and α -synuclein aggregation [117, 121]. On the other hand, tissue thinning has been attributed to degeneration secondary to impaired dopaminergic cells [121, 124], a subgroup of amacrine cells in the inner retina [85]. Another speculation of the thinning of retinal layers is a secondary change due to the α -synuclein deposition and comes from animal studies that facilitate parallel retinal tissue assessment. Our recent findings in the transgenic PD mice model (M83 expressing human A53 T variant α -synuclein) showed that there was a significantly thinner OPL and ONL, which correlated with the pathological α -synuclein accumulation in the ONL [139]. Similarly, in Xu et al.'s study [73], the phosphorylated Ser129 α -synuclein accumulation was detected in the OPL of the same mouse model (M83), along with the degeneration of photoreceptor cells, including the loss of photoreceptor terminals in the OPL, and attenuated outer retinal photoreceptor function. Another finding in our toxin-induced PD mice model (MPTP) [140] has shown a significantly thinner OPL and impaired outer retinal photoreceptor function compared to the wildtype controls, indicating a toxin-mediated mechanism may be underlying the alteration of the outer retina. Other mechanisms have also been proposed as outer retinal structure-related changes, such as impaired glutamatergic pathways [127] and deprivation of docosahexaenoic acid, a material that maintains the renewal of the photoreceptor

outer segment and was assumed to influence retinal degenerative disorders [119].

Conclusion

Color vision deficiency is commonly observed among those with PD and prodromal PD, and in some cases, color vision deficiency can be detected even a decade before the onset of motor symptoms. Defects have been reported in the red–green axis as well as the blue–yellow axis. The association between color vision loss and the disease severity of PD remains uncertain, requiring longitudinal observation in a larger cohort with consistent methodologies. Given scalability issues with current color vision tests, the development of widely implementable color vision tests for population screening would be very useful. Whether vision assessments should be included in future PD rating scales warrants future consideration to assist in diagnosis, progression, and severity grading. OCT imaging is widespread in the community, affording an opportunity for population-based screening of PD. The outer retinal layers observed by OCT include the photoreceptor and retinal pigment epithelium cells, and changes in outer retinal thickness may be useful as a more disease-specific measure in pwPD than generalized inner retinal thinning. Further work is needed to pinpoint the optimal OCT imaging approach and location to return the most useful diagnostic and monitoring metrics.




Fig. 3 A representative single-line OCT scan. **a** An enface image of the posterior retina. The yellow circle represents the macular region of the retina, 6 mm X 6 mm in size. The green line indicates the path of a single macular OCT line scan displayed in panel **(b)**. **b** A cross-sectional (B-scan) OCT image of the posterior retina in the horizontal meridian. The cross-sectional OCT image returns retinal layers including the **inner retina**: RNFL (black layer), retinal nerve fiber layer; GCL (orange layer), ganglion cell layer; IPL (beige layer), inner plexiform layer; INL (yellow layer), inner nuclear layer; and the **outer retina**: OPL (green layer), outer plexiform layer; ONL (light-

blue layer), outer nuclear layer; PRL (dark-blue layer), photoreceptors (rods and cones) layer; RPE (pink layer), retinal pigment epithelium. The macular region is a key area which is responsible for visual acuity and color vision. There are three main types of neurons in the retina located in different layers: 1. photoreceptor cells (dendrites PRL, somas in ONL, and axons in OPL); 2. bipolar cells (dendrites in OPL, somas in INL, and axons in IPL); 3. ganglion cells (dendrites in IPL, somas in GCL, and axons in RNFL), and visual signals are transmitted from outermost to innermost layer of the retina

Table 2 Outer retinal thickness in OCT among people with PD and iRBD

Papers	Numbers of participants (eyes)			Mean age (years)	Mean Hoehn & Yahr scale	Mean disease duration (year)	OCT Scanning			Region of interest	Findings in outer retinal layers					
	PD	HC	PD/HC				Machine	Scan mode	Segmentation method		OPL	ONL	PRL	RPE		
A. Volume OCT scans																
Chrysoy et al. (2024) [104]	121 (242)	100 (200)	65.1	62.7	2	< 0.25	Canon HS-100 OCT	Volumetric macular region	Automatic	Mean thickness of the macular area (6 mm X 6 mm)	↔	↔	↔	↔	↔	ISOS: ↔ OSL: ↔ OPR: ↔
Tran et al. (2024) [35]	16 (11)	21 (15)	61	57	NA	5	Spectralis OCT	Volumetric macular region	Automatic	Mean thickness of the macular area (6 mm X 6 mm)	↔	↓	NA	↔	↔	↔
Terravochia et al. (2024) [114]	21 (41)	17 (33)	61.5	65.1	NA	2.3	Cirrus HD-OCT	Volumetric macular region	Semi-automated	Mean thickness of the macular area (6 mm X 6 mm)	↔	↓	NA	↔	↔	↔
Mello et al. (2022) [37]	30 (41)	19 (38)	58.5	52.5	2.1	9.1	Spectralis OCT	Volumetric macular region	Semi-automated	Mean thickness of the macular area (individual sectors in 6 mm X 6 mm ETDRS)	↔	↔	↔	↔	↔	↔
Zhang et al. (2021) [115]	52 (100)	100 (200)	57.9	56.6	1.5	2.5	VG200 (SS-OCT)	Volumetric macular region	Semi-automated	Mean thickness of the macular area (individual sectors in 6 mm X 6 mm ETDRS)	ORL: ↓	↔	↔	↔	↔	↔
Rascunà et al. (2021) [25]	19 (37) (iRBD)	17 (33)	58.8	65.1	NA	NA	Cirrus HD-OCT	Volumetric macular region	Automatic	Mean thickness of the macular area (6 mm X 6 mm)	↓	↓	NA	↔	↔	↔

Table 2 (continued)

Papers	Numbers of participants (eyes)				Mean age (years)	Mean Hoehn & Yahr scale	Mean disease duration (year)	OCT Scanning		Region of interest	Findings in outer retinal layers				
	PD	HC	HC	PD				Machine	Scan mode		Segmentation method	OPL	ONL	PRL	RPE
Rascunà et al. (2020) [116]	21 (41)	17 (33)	61.5	65.1	1.9	2.3	Cirrus HD-OCT	Volumetric macular region	Automatic	Mean thickness of the macular area (6 mm X 6 mm)	↔	↓	NA	↔	
Unlu et al. (2018) [117]	58 (116)	30 (60)	60.5	60.2	2.1	7.1	Spectralis OCT	Volumetric macular region	Automatic	Mean thickness and mean volume of the macular area (6 mm X 6 mm)	↔	↓	↔	↓	
Uchida et al. (2018) [118, 119]	22 (22)	36 (36)	62.9	65.1	NA	NA	Cirrus HD-OCT	Volumetric macular region	Automatic	Mean thickness at the fovea central, temporally and nasally 1 mm from the fovea. Mean volume of the macular area (6 mm X 6 mm)	Both thickness and volume NA	ONL+ PRL: ↔	↔	NA	
Maitlankody et al. (2015) [120]	30 (60)	30 (60)	53.4	53.5	1.7	5.3	Spectralis OCT	Radial macular scans	Automatic	Mean thickness at 0.5 mm and 1 mm from the fovea	ORL: thinner in the right nasal quadrant 0.5 mm from the fovea and the right inferior quadrant 1 mm away from the fovea	↔	↓	NA	NA
Choroștecki et al. (2015) [121]	52 (101)	24 (46)	65.8	59.8	2.0	6.4	Spectralis OCT	Volumetric macular region	Automatic	Mean volume of the macular area (6 mm X 6 mm)	↑	↓	NA	NA	
Müller et al. (2014) * [122]	39 (39)	33 (33)	NA	NA	NA	NA	Spectralis OCT	Volumetric macular scans	Semi-automated	Mean thickness of the macular area (6 mm X 6 mm)	↔	↔	ISOS: ↓ OPT: ↔	NA	

Table 2 (continued)

Papers	Numbers of participants (eyes)				Mean age (years)	Mean Hoehn & Yahr scale	Mean disease duration (year)	OCT Scanning		Region of interest	Findings in outer retinal layers					
	PD	HC	PD	HC				Machine	Scan mode		Segmentation method	OPL	ONL	PRL	RPE	
Garcia-Martin et al. (2014) [123]	129 (129)	129 (129)	68.8	69.0	2.70	8.4	Spectralis OCT	Volumetric macular scans	Automatic	Mean thickness of the macular area (6 mm X 6 mm)	↓	↔	↔	↔	↔	
Roth et al. (2014) [124]	68 (114)	32 (63)	68.8	64.7	NA	7.2	Cirrus HD-OCT	Macular Cube region	Automatic	Mean thickness of the macular area (6 mm X 6 mm)	INL+OPL: ↔	ONL+PRL: ↓	↔	↔	NA	
B. Single line scan																
Schneider et al. (2014) [125]	65	41	66.2	65.1	NA	8.9	Cirrus HD-OCT	single horizontal foveal scan	Semi-automated	Mean thickness of the macular area (4.5 mm)	↔	↔	ONL+PRL: ↔	↔	↔	NA
Lee et al. (2014) [126]	61 (56)	30 (30)	69.6	64.8	2.2	6.0	Opko OTI SD-OCT	single horizontal foveal scan	Manual	The fovea center; temporally 1 mm, 2 mm, and 3 mm, nasally 1 mm from the fovea	↔	↔	ONL + PIS: ↔	POS + RPE: ↔	↔	↔
Albrecht et al. (2012) [38]	40 (80)	35 (70)	61.2	NA	2.5	8.1	Spectralis OCT	Single horizontal foveal scan	Manual	OPL: the thickest points on nasally and temporally of the macular ONL: the central thickest point	↔	↔	↔	↔	↔	NA

OCT optical coherence tomography; PD Parkinson's disease; HC healthy controls; NA, not applicable (data are not provided); ↔, no significant difference; ↓, significant decrease; ↑, significant increase; OPL outer plexiform layer; ONL outer nuclear layer; PRL photoreceptor layer; IS/OS, inner segment/outer segment junction; RPE retinal pigment epithelium; PIS, photoreceptor inner segment; POS, photoreceptor outer segment; OPT outer photoreceptor tips; OSL, outer segment layer; OPR outer segment to RPE junction; ORL outer retinal layer; INL inner nuclear layer; ETDRS Early Treatment Diabetic Retinopathy Study grid, contains three rings including the foveal ring (a circle of 1 mm diameter), inner ring (inner diameter of 1 mm and outer diameter of 3 mm), and outer ring (inner diameter of 3 mm and outer diameter of 6 mm)

*Further analysis on a subset of Albrecht et al. (2012)'s cohort




Fig. 4 Forest plot showing Cohen's d effect size (95% CI) in studies reporting the thickness of individual outer retinal layers [a OPL, b ONL, c PRL, and d RPE]. Each study is represented by a dot (mean Cohen's d) with error bars (95% CI). Positive values represent thickening of the layers in the PD or iRBD group compared to healthy

controls, while negative values suggest thinning of the layer. Asterisks (*) indicate significant differences between groups; #1 and #2 represent unilateral PD and bilateral PD, respectively; CI Confidence interval; PD Parkinson's disease; iRBD idiopathic rapid eye movement sleep behavior disorder

Acknowledgements The authors would like to thank Dr. John Parkes and Dr. Amanda Douglass for facilitating photography of their color vision tests used in this manuscript.

Author contributions JL performed the literature search, analyzed the data, and drafted the first version of the manuscript. CN and JA critically revised the work. All authors read and approved the final manuscript.

Funding Open Access funding enabled and organized by CAUL and its Member Institutions. JL is supported by the Australian Rotary Health/Rotary Clubs of District 9800 Parkinson's Disease Research PhD Scholarship, as well as a Melbourne Research Scholarship (Fee offset) from the University of Melbourne; CN, DF, BB, and PYL are supported by a US Department of Defense grant (CDMRP PD210055); CN, DF, TW, BB, and PYL are supported by MDHS Large Equipment Grant Scheme, The University of Melbourne.

Data availability All original sources are cited in the manuscript. Data extracted and analyzed in this review are available from the corresponding author upon request.

Declarations

Conflicts of interest The authors have no relevant financial or non-financial interests to disclose.

Ethical approval Not applicable. The manuscript does not contain clinical studies or patient data.

Informed consent Not applicable. The manuscript does not contain clinical studies or patient data.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Albin R, Grotewold N (2023) What is the Parkinson pandemic? *Mov Disord* 38(12):2141–2144. <https://doi.org/10.1002/mds.29637>

2. Dorsey ER, Bloem BR (2018) The Parkinson pandemic—a call to action. *JAMA Neurol* 75(1):9–10. <https://doi.org/10.1001/jamaneurol.2017.3299>
3. Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord* 30(12):1591–1601. <https://doi.org/10.1002/mds.26424>
4. Greffard S, VERNY M, Bonnet A-M et al (2006) Motor score of the unified parkinson disease rating scale as a good predictor of lewy body-associated neuronal loss in the Substantia Nigra. *Arch Neurol* 63(4):584–588. <https://doi.org/10.1001/archneur.63.4.584>
5. Fearnley JM, Lees AJ (1991) AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY. *Brain* 114(Pt 5):2283–2301. <https://doi.org/10.1093/brain/114.5.2283>
6. Kalia LV, Lang AE (2015) Parkinson's disease. *The Lancet* 386(9996):896–912. [https://doi.org/10.1016/S0140-6736\(14\)61393-3](https://doi.org/10.1016/S0140-6736(14)61393-3)
7. Munhoz RP, Tumas V, Pedroso JL, Silveira-Moriyama L (2024) The clinical diagnosis of Parkinson's disease. *Arq Neuropsiquiatr* 82(6):1–10. <https://doi.org/10.1055/s-0043-177775>
8. Simuni T, Chahine LM, Poston K et al (2024) A biological definition of neuronal α -synuclein disease: towards an integrated staging system for research. *Lancet Neurol* 23(2):178–190. [https://doi.org/10.1016/S1474-4422\(23\)00405-2](https://doi.org/10.1016/S1474-4422(23)00405-2)
9. Höglinger GU, Adler CH, Berg D et al (2024) A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria. *Lancet Neurol* 23(2):191–204. [https://doi.org/10.1016/S1474-4422\(23\)00404-0](https://doi.org/10.1016/S1474-4422(23)00404-0)
10. Davidsdottir S, Cronin-Golomb A, Lee A (2005) Visual and spatial symptoms in Parkinson's disease. *Vision Res* 45(10):1285–1296. <https://doi.org/10.1016/j.visres.2004.11.006>
11. Hamedani AG, Abraham DS, Maguire MG, Willis AW (2020) Visual impairment is more common in Parkinson's disease and is a risk factor for poor health outcomes. *Mov Disord* 35(9):1542–1549. <https://doi.org/10.1002/mds.28182>
12. Hamedani AG, Willis AW (2020) Self-reported visual dysfunction in Parkinson disease: the survey of health, ageing and retirement in Europe. *Eur J Neurol* 27(3):484–489. <https://doi.org/10.1111/ene.14092>
13. Han G, Han J, Han K, Youn J, Chung TY, Lim DH (2020) Visual acuity and development of Parkinson's disease: a nationwide cohort study. *Mov Disord* 35(9):1532–1541. <https://doi.org/10.1002/mds.28184>
14. Zhu Z, Hu W, Liao H et al (2021) Association of visual impairment with risk for future Parkinson's disease. *EclinicalMedicine* 42:101189. <https://doi.org/10.1016/j.eclinm.2021.101189>
15. Urwyler P, Nef T, Killen A et al (2014) Visual complaints and visual hallucinations in Parkinson's disease. *Parkinsonism Relat Disord* 20(3):318–322. <https://doi.org/10.1016/j.parkreldis.2013.12.009>
16. Teive HAG, Bertucci Filho DC, Munhoz RP (2016) Unusual motor and non-motor symptoms and signs in the early stage of Parkinson's disease. *Arq Neuropsiquiatr* 74(10):781–784. <https://doi.org/10.1590/0004-282X20160126>
17. Hughes KC, Gao X, Baker JM et al (2021) Non-motor features of Parkinson's disease in women. *J Parkinsons Dis* 11(3):1237–1246. <https://doi.org/10.3233/JPD-202409>
18. Hughes KC, Gao X, Baker JM et al (2018) Non-motor features of Parkinson's disease in a nested case-control study of US men. *J Neurol Neurosurg Psychiatry* 89(12):1288–1295. <https://doi.org/10.1136/jnnp-2018-318275>
19. Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB (2019) Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. *Brain* 142(7):2051–2067. <https://doi.org/10.1093/brain/awz111>
20. Postuma RB, Iranzo A, Hu M et al (2019) Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain* 142(3):744–759. <https://doi.org/10.1093/brain/awz030>
21. Iranzo A, Fernández-Arcos A, Tolosa E et al (2014) Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. *PLoS ONE* 9(2):e89741. <https://doi.org/10.1371/journal.pone.0089741>
22. Schenck CH, Boeve BF, Mahowald MW (2013) Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. *Sleep Med* 14(8):744–748. <https://doi.org/10.1016/j.sleep.2012.10.009>
23. Dauvilliers Y, Schenck CH, Postuma RB et al (2018) REM sleep behaviour disorder. *Nat Rev Dis Primers* 4(1):19. <https://doi.org/10.1038/s41572-018-0016-5>
24. Hu MT (2020) REM sleep behavior disorder (RBD). *Neurobiol Dis* 143:104996. <https://doi.org/10.1016/j.nbd.2020.104996>
25. Rascunà C, Cicero CE, Chisari CG et al (2021) Retinal thickness and microvascular pathway in Idiopathic Rapid eye movement sleep behaviour disorder and Parkinson's disease. *Parkinsonism Relat Disord* 88:40–45. <https://doi.org/10.1016/j.parkreldis.2021.05.031>
26. Harnois C, Di Paolo T (1990) Decreased dopamine in the retinas of patients with Parkinson's disease. *Invest Ophthalmol Vis Sci* 31(11):2473–2475
27. Biehlmaier O, Alam M, Schmidt WJ (2007) A rat model of Parkinsonism shows depletion of dopamine in the retina. *Neurochem Int* 50(1):189–195. <https://doi.org/10.1016/j.neuint.2006.08.001>
28. Nguyen-Legros J (1988) Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. *Surg Radiol Anat* 10(2):137–144. <https://doi.org/10.1007/BF02307822>
29. Ortuño-Lizarán I, Beach TG, Serrano GE, Walker DG, Adler CH, Cuenca N (2018) Phosphorylated α -synuclein in the retina is a biomarker of Parkinson's disease pathology severity. *Mov Disord* 33(8):1315–1324. <https://doi.org/10.1002/mds.27392>
30. Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S (2014) α -synuclein in the inner retina in Parkinson disease. *Ann Neurol* 75(6):964–966. <https://doi.org/10.1002/ana.24182>
31. Mammadova N, Summers CM, Kokemuller RD et al (2019) Accelerated accumulation of retinal α -synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson's disease. *Neurobiol Dis* 121:1–16. <https://doi.org/10.1016/j.nbd.2018.09.013>
32. Price DL, Rockenstein E, Mante M et al (2016) Longitudinal live imaging of retinal α -synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies. *Sci Rep*. <https://doi.org/10.1038/srep29523>
33. Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR (2016) Visual dysfunction in Parkinson's disease. *Brain* 139(11):2827–2843. <https://doi.org/10.1093/brain/aww175>
34. Guo L, Normando E, Shah P, De Groef L, Cordeiro M (2018) Oculo-visual abnormalities in Parkinson's disease: Possible value as biomarkers. *Mov Disord* 33(9):1390–1406. <https://doi.org/10.1002/mds.27454>
35. Tran KKN, Lee PY, Finkelstein DI et al (2024) Altered outer retinal structure, electrophysiology and visual perception in Parkinson's Disease. *J Parkinsons Dis* 14(1):167–180. <https://doi.org/10.3233/JPD-230293>
36. Weil RS (2020) Visual Dysfunction and Parkinson's Disease. *Mov Disord* 35(9):1499–1501. <https://doi.org/10.1002/mds.28212>
37. Mello LGM, Paraguay IBB, de Andrade T et al (2022) Electroretinography reveals retinal dysfunction in Parkinson's disease

- despite normal high-resolution optical coherence tomography findings. *Parkinsonism Relat Disord* 101:90–95. <https://doi.org/10.1016/j.parkreldis.2022.06.018>
38. Albrecht P, Müller AK, Südmeyer M et al (2012) Optical coherence tomography in parkinsonian syndromes. *PLoS ONE* 7(4):e34891. <https://doi.org/10.1371/journal.pone.0034891>
 39. Mailankody P, Lenka A, Pal PK (2019) The role of optical coherence tomography in Parkinsonism: a critical review. *J Neurol Sci* 403:67–74. <https://doi.org/10.1016/j.jns.2019.06.009>
 40. Wagner SK, Romero-Bascones D, Cortina-Borja M et al (2023) Retinal optical coherence tomography features associated with incident and prevalent Parkinson disease. *Neurology* 101(16):E1581–E1593. <https://doi.org/10.1212/WNL.0000000002007727>
 41. Christou EE, Asproudis I, Asproudis C, Giannakis A, Stefanidou M, Konitsiotis S (2022) Macular microcirculation characteristics in Parkinson's disease evaluated by OCT-Angiography: a literature review. *Semin Ophthalmol* 37(3):399–407. <https://doi.org/10.1080/08820538.2021.1987482>
 42. Robbins CB, Thompson AC, Bhullar PK et al (2021) Characterization of retinal microvascular and choroidal structural changes in Parkinson disease. *JAMA Ophthalmol* 139(2):182–188. <https://doi.org/10.1001/jamaophthalmol.2020.5730>
 43. Katsimpris A, Papadopoulos I, Voulgari N et al (2023) Optical coherence tomography angiography in Parkinson's disease: a systematic review and meta-analysis. *Eye (Basingstoke)* 37(14):2847–2854. <https://doi.org/10.1038/s41433-023-02438-7>
 44. Deng Y, Jie C, Wang J, Liu Z, Li Y, Hou X (2022) Evaluation of retina and microvascular changes in the patient with Parkinson's disease: A systematic review and meta-analysis. *Front Med (Lausanne)*. <https://doi.org/10.3389/fmed.2022.957700>
 45. Serdar CC, Cihan M, Yücel D, Serdar MA (2021) Sample size power and effect size revisited: Simplified and practical approach in pre-clinical clinical and laboratory studies. *Biochem Med (Zagreb)* 31(1):1–27. <https://doi.org/10.11613/BM.2021.010502>
 46. Gegenfurtner KR, Kiper DC (2003) Color vision. *Annu Rev Neurosci* 26:181–206. <https://doi.org/10.1146/annurev.neuro.26.041002.131116>
 47. Simunovic MP (2010) Colour vision deficiency. *Eye* 24(5):747–755. <https://doi.org/10.1038/eye.2009.251>
 48. Simunovic MP (2016) Acquired color vision deficiency. *Surv Ophthalmol* 61(2):132–155. <https://doi.org/10.1016/j.survophthal.2015.11.004>
 49. Cole BL (2007) Assessment of inherited colour vision defects in clinical practice. *Clin Exp Optom* 90(3):157–175. <https://doi.org/10.1111/j.1444-0938.2007.00135.x>
 50. Müller T, Kuhn W, Büttner T, Przuntek H (1999) Colour vision abnormalities and movement time in Parkinson's disease. *Eur J Neurol* 6(6):711–715. <https://doi.org/10.1046/j.1468-1331.1999.660711.x>
 51. Büttner T, Kuhn W, Müller TH, Patzold T, Heidbrink K, Przuntek H (1995) Distorted color discrimination in 'de nova' parkinsonian patients. *Neurology* 45(2):386–387. <https://doi.org/10.1212/WNL.45.2.386>
 52. Price M, Feldman RG, Adelberg D, Kayne H (1992) Abnormalities in color vision and contrast sensitivity in Parkinson's disease. *Neurology* 42(4):887–890. <https://doi.org/10.1212/wnl.42.4.887>
 53. Oh YS, Kim JS, Chung SW et al (2011) Color vision in Parkinson's disease and essential tremor. *Eur J Neurol* 18(4):577–583. <https://doi.org/10.1111/j.1468-1331.2010.03206.x>
 54. Diederich NJ, Vannina P, Géraldine H, Olivier R, Sara B, Michel V (2010) Discriminative power of different nonmotor signs in early Parkinson's disease A case-control study. *Mov Disord* 25(7):882–887. <https://doi.org/10.1002/mds.22963>
 55. Haug BA, Kolle RU, Trenkwalder C, Oertel WH, Paulus W (1995) Predominant affection of the blue cone pathway in Parkinson's disease. *Brain* 118(pt 3):771–778. <https://doi.org/10.1093/brain/118.3.771>
 56. Aliu B, Zimmermann HG, Oberwahrenbrock T, Isensee J, Müller T, Paul F (2018) Self-perception and determinants of color vision in Parkinson's disease. *J Neural Transm* 125(2):145–152. <https://doi.org/10.1007/s00702-017-1812-x>
 57. Müller T, Weitalla D, Peters S, Kohla K, Przuntek H (2002) Progress of visual dysfunction in Parkinson's disease. *Acta Neurol Scand* 105(4):256–260. <https://doi.org/10.1034/j.1600-0404.2002.1o154.x>
 58. Diederich NJ, Rema R, Sue L, Goetz Christopher G (2002) Progressive worsening of spatial and chromatic processing deficits in Parkinson Disease. *Arch Neurol* 59(8):1249–1252. <https://doi.org/10.1001/archneur.59.8.1249>
 59. Satue M, Rodrigo MJ, Obis J et al (2017) Evaluation of progressive visual dysfunction and retinal degeneration in patients with parkinson's disease. *Invest Ophthalmol Vis Sci* 58(2):1151–1157. <https://doi.org/10.1167/iovs.16-20460>
 60. Kim S, Choi JH, Woo KA, Joo JY, Jeon B, Lee JY (2024) Clinical correlates of pareidolias and color discrimination deficits in idiopathic REM sleep behavior disorder and Parkinson's disease. *J Neural Transm* 131(2):141–148. <https://doi.org/10.1007/s00702-023-02724-4>
 61. Sun L, Zhang H, Gu Z, Cao M, Li D, Chan P (2014) Stereopsis impairment is associated with decreased color perception and worse motor performance in Parkinson's disease. *Eur J Med Res* 19(1):1–7. <https://doi.org/10.1186/2047-783X-19-29>
 62. Pieri V, Diederich NJ, Raman R, Goetz CG (2000) Decreased color discrimination and contrast sensitivity in Parkinson's disease. *J Neurol Sci* 172(1):7–11. [https://doi.org/10.1016/s0022-510x\(99\)00204-x](https://doi.org/10.1016/s0022-510x(99)00204-x)
 63. Veselá O, Růžička E, Jech R et al (2001) Colour discrimination impairment is not a reliable early marker of Parkinson's disease. *J Neurol* 248(11):975–978. <https://doi.org/10.1007/s00415017005>
 64. Postuma RB, Gagnon JF, Vendette M, Montplaisir JY (2009) Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. *Brain* 132(12):3298–3307. <https://doi.org/10.1093/brain/awp244>
 65. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J (2006) Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. *Neurology* 66:845–851. <https://doi.org/10.1212/01.wnl.0000203648.80727.5b>
 66. Li Y, Zhang H, Mao W et al (2019) Visual dysfunction in patients with idiopathic rapid eye movement sleep behavior disorder. *Neurosci Lett* 709:134360. <https://doi.org/10.1016/j.neulet.2019.134360>
 67. Kertelge L, Brüggemann N, Schmidt A et al (2010) Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease. *Mov Disord* 25(15):2665–2669. <https://doi.org/10.1002/mds.23272>
 68. Silva MF, Faria P, Regateiro FS et al (2005) Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease. *Brain* 128(10):2260–2271. <https://doi.org/10.1093/brain/awh581>
 69. Dušek P, Ibarburu VLL, Bezdicek O et al (2019) Relations of non-motor symptoms and dopamine transporter binding in REM sleep behavior disorder. *Sci Rep* 9(1):15463. <https://doi.org/10.1038/s41598-019-51710-y>
 70. Ehrminger M, Latimier A, Pyatigorskaya N et al (2016) The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. *Brain* 139(Pt 4):1180–1188. <https://doi.org/10.1093/brain/aww030>

71. Büttner T, Kuhn W, Patzold T, Przuntek H (1994) L-Dopa improves colour vision in Parkinson's disease. *J Neural Transm* 7(1):13–19. <https://doi.org/10.1007/BF02252659>
72. Morris HR, Spillantini MG, Sue CM, Williams-Gray CH (2024) The pathogenesis of Parkinson's disease. *Lancet* 403(10423):293–304. [https://doi.org/10.1016/S0140-6736\(23\)01478-2](https://doi.org/10.1016/S0140-6736(23)01478-2)
73. Xu T, Liu X, Lin X et al (2024) Abnormal α -synuclein aggregates cause synaptic- and microcircuit-specific deficits in the retinal rod pathway. *Am J Pathol* 194(5):796–809. <https://doi.org/10.1016/j.ajpath.2024.01.017>
74. Ortuño-Lizarán I, Sánchez-Sáez X, Lax P et al (2020) Dopaminergic retinal cell loss and visual dysfunction in parkinson disease. *Ann Neurol* 88(5):893–906. <https://doi.org/10.1002/ana.25897>
75. Curcio CA, Sloan KR, Kalina RE, Hendrickson AE, Cac O, Science C (1990) Human photoreceptor topography. *J Comp Neurol* 292(4):497–523. <https://doi.org/10.1002/cne.902920402>
76. Birch J, Kolle RU, Kunkel M, Paulus W, Upadhyay P (1998) Acquired colour deficiency in patients with Parkinson's disease. *Vision Res* 38:3421–3426. [https://doi.org/10.1016/S0042-6989\(97\)00398-2](https://doi.org/10.1016/S0042-6989(97)00398-2)
77. Regan BC, Freudenthaler N, Kolle R, Mollon JD, Paulus W (1998) Colour discrimination thresholds in Parkinson's disease: results obtained with a rapid computer-controlled colour vision test. *Vision Res* 38(21):3427–3432. [https://doi.org/10.1016/S0042-6989\(97\)00402-1](https://doi.org/10.1016/S0042-6989(97)00402-1)
78. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. *Neurology* 17(5):427–442. <https://doi.org/10.1212/wnl.17.5.427>
79. Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 23(15):2129–2170. <https://doi.org/10.1002/mds.22340>
80. Perlmutter JS (2009) Assessment of parkinson disease manifestations. *Curr Protoc Neurosci*. <https://doi.org/10.1002/0471142301.ns1001s49>
81. Bohnen NI, Haugen J, Ridder A et al (2017) Color discrimination errors associate with axial motor impairments in Parkinson's Disease. *Mov Disord Clin Pract* 4(6):864–869. <https://doi.org/10.1002/mdc3.12527>
82. Matar E, Phillips JR, Martens K, Halliday GM, Lewis SJG (2019) impaired color discrimination—a specific marker of hallucinations in lewy body disorders. *J Geriatr Psychiatry Neurol* 32(5):257–264. <https://doi.org/10.1177/0891988719845501>
83. Bertrand JA, Bedetti C, Postuma RB et al (2012) Color discrimination deficits in Parkinson's disease are related to cognitive impairment and white-matter alterations. *Mov Disord* 27(14):1781–1788. <https://doi.org/10.1002/mds.25272>
84. Müller T, Meisel M, Russ H, Przuntek H (2003) Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients. *J Neurol Sci* 213(1–2):61–65. [https://doi.org/10.1016/S0022-510X\(03\)00150-3](https://doi.org/10.1016/S0022-510X(03)00150-3)
85. Archibald NK, Clarke MP, Mosimann UP, Burn DJ (2011) Visual symptoms in Parkinson's disease and Parkinson's disease dementia. *Mov Disord* 26(13):2387–2395. <https://doi.org/10.1002/mds.23891>
86. Nguyen-Tri D, Overbury O, Faubert J (2003) The role of lenticular senescence in age-related color vision changes. *Investig Ophthalmol Vis Sci* 44:3698–3704. <https://doi.org/10.1167/iovs.02>
87. Anderson AJ, Johnston AW (2015) Test/retest and inter-test agreement of color aptitude measures. *Color Res Appl* 40(3):224–231. <https://doi.org/10.1002/col.21876>
88. Winograd-Gurvich C, Georgiou-Karistianis N, Fitzgerald PB, Millist L, White OB (2006) Self-paced saccades and saccades to oddball targets in Parkinson's disease. *Brain Res* 1106(1):134–141. <https://doi.org/10.1016/j.brainres.2006.05.103>
89. Almer Z, Klein KS, Marsh L, Gerstenhaber M, Repka MX (2012) Ocular motor and sensory function in Parkinson's disease. *Ophthalmology* 119(1):178–182. <https://doi.org/10.1016/j.ophtha.2011.06.040>
90. Leite Silva A, Gonçalves de Oliveira R, Diógenes G et al (2023) Premotor, nonmotor and motor symptoms of Parkinson's Disease: a new clinical state of the art. *Ageing Res Rev* 84:101834. <https://doi.org/10.1016/j.arr.2022.101834>
91. Iregren A, Andersson M, Nylén P (2002) Color vision and occupational chemical exposures: I an overview of tests and effects. *Neurotoxicology* 23(6):719–733. [https://doi.org/10.1016/S0161-813X\(02\)00088-8](https://doi.org/10.1016/S0161-813X(02)00088-8)
92. Kupersmith MJ, Shakin E, Siegel IM, Lieberman A (1982) Visual system abnormalities in patients With Parkinson's disease. *Arch Neurol* 39(5):284–286
93. Kaur M, Saxena R, Singh D, Behari M, Sharma P, Menon V (2015) Correlation between structural and functional retinal changes in Parkinson disease. *J Neuroophthalmol* 35(3):254–258. <https://doi.org/10.1097/WNO.0000000000000240>
94. Hasanov S, Demirkilinc Biler E, Acarer A, Akkın C, Colakoglu Z, Uretmen O (2019) Functional and morphological assessment of ocular structures and follow-up of patients with early-stage Parkinson's disease. *Int Ophthalmol* 39(6):1255–1262. <https://doi.org/10.1007/s10792-018-0934-y>
95. Suci VI, Suci CI, Nicoară SD, Perju-Dumbravă L (2022) Circumpapillary retinal nerve fiber layer OCT imaging in a parkinson's disease cohort—a multidisciplinary approach in a clinical research hospital. *J Pers Med* 12(1):80. <https://doi.org/10.3390/jpm12010080>
96. Štenc Bradvica I, Bradvica M, Matic S, Reisz-Majić P (2015) Visual dysfunction in patients with Parkinson's disease and essential tremor. *Neurol Sci* 36(2):257–262. <https://doi.org/10.1007/s10072-014-1930-2>
97. Haug BA, Trenkwalder C, Arden GB, Oertel WH, Paulus W (1994) Visual thresholds to low-contrast pattern displacement, color contrast, and luminance contrast stimuli in Parkinson's Disease. *Mov Disord* 9(5):563–570. <https://doi.org/10.1002/mds.870090510>
98. Rabin J, Gooch J, Ivan D (2011) Rapid quantification of color vision: The cone contrast test. *Invest Ophthalmol Vis Sci* 52(2):816–820. <https://doi.org/10.1167/iovs.10-6283>
99. Mehta U, Diep A, Nguyen K et al (2020) Quantifying color vision changes associated with cataracts using cone contrast thresholds. *Transl Vis Sci Technol* 9(12):1–10. <https://doi.org/10.1167/tvst.9.12.11>
100. Barbur JL, Rodriguez-Carmona M, Evans BEW (2021) Color vision assessment-3 An efficient, two-step, color assessment protocol. *Color Res Appl* 46(1):33–45. <https://doi.org/10.1002/col.22599>
101. Seshadri J, Christensen J, Bassi CJ (2005) Evaluation of the new web-based “Colour Assessment and Diagnosis” Test. *Optom Vis Sci* 82(10):882–885. <https://doi.org/10.1097/OI.0px.0000182211.48498.4e>
102. Huang D, Swanson E, Lin C et al (1991) Optical coherence tomography. *Science* 254(5035):1178–1181
103. Podoleanu AG (2005) Optical coherence tomography. *Br J Radiol* 78(935):976–988. <https://doi.org/10.1259/bjr/55735832>
104. Chrysou A, Heikka T, van der Zee S, Boertien JM, Jansonius NM, van Laar T (2024) Reduced thickness of the retina in de novo Parkinson's disease shows a distinct pattern different from glaucoma. *J Parkinsons Dis* 14(3):507–519. <https://doi.org/10.3233/JPD-223481>

105. Fujimoto J, Swanson E (2016) The development, commercialization, and impact of optical coherence tomography. *Invest Ophthalmol Vis Sci*. <https://doi.org/10.1167/iovs.16-19963>
106. Aumann S, Donner S, Fischer J, Müller F (2019) Optical Coherence Tomography (OCT): Principle and Technical Realization. In: Bille J (ed) *High resolution imaging in microscopy and ophthalmology*. Springer, Cham, pp 59–85. https://doi.org/10.1007/978-3-030-16638-0_3
107. Huang L, Zhang D, Ji J, Wang Y, Zhang R (2021) Central retina changes in Parkinson's disease: a systematic review and meta-analysis. *J Neurol* 268(12):4646–4654. <https://doi.org/10.1007/s00415-020-10304-9>
108. Chrysou A, Jansonius NM, van Laar T (2019) Retinal layers in Parkinson's disease: a meta-analysis of spectral-domain optical coherence tomography studies. *Parkinsonism Relat Disord* 64:40–49. <https://doi.org/10.1016/j.parkreldis.2019.04.023>
109. Lee YW, Lim MN, Lee JY, Yoo YJ (2023) Central retina thickness measured with spectral-domain optical coherence tomography in Parkinson disease: a meta-analysis. *Medicine (United States)* 102(40):E35354. <https://doi.org/10.1097/MD.00000000000035354>
110. Zhou WC, Tao JX, Li J (2021) Optical coherence tomography measurements as potential imaging biomarkers for Parkinson's disease: a systematic review and meta-analysis. *Eur J Neurol* 28(3):763–774. <https://doi.org/10.1111/ene.14613>
111. Yu JG, Feng YF, Xiang Y et al (2014) Retinal nerve fiber layer thickness changes in Parkinson disease: A meta-analysis. *PLoS ONE* 9(1):e85718. <https://doi.org/10.1371/journal.pone.0085718>
112. Alves JN, Westner BU, Højlund A, Weil RS, Dalal SS (2023) Structural and functional changes in the retina in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 94(6):448–456. <https://doi.org/10.1136/jnnp-2022-329342>
113. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A (2004) Retinal nerve fiber layer thinning in Parkinson disease. *Vision Res* 44(24):2793–2797. <https://doi.org/10.1016/j.visres.2004.06.009>
114. Terravecchia C, Mostile G, Chisari CG et al (2024) Retinal thickness in essential tremor and early parkinson disease: exploring diagnostic insights. *J Neuroophthalmol* 44(1):35–40. <https://doi.org/10.1097/wno.0000000000001959>
115. Zhang Y, Zhang D, Gao Y et al (2021) Retinal flow density changes in early-stage Parkinson's disease investigated by swept-source optical coherence tomography angiography. *Curr Eye Res* 46(12):1886–1891. <https://doi.org/10.1080/02713683.2021.1933054>
116. Rascunà C, Russo A, Terravecchia C et al (2020) Retinal thickness and microvascular pattern in early Parkinson's disease. *Front Neurol* 11:533375. <https://doi.org/10.3389/fneur.2020.533375>
117. Unlu M, Gulmez Sevim D, Gultekin M, Karaca C (2018) Correlations among multifocal electroretinography and optical coherence tomography findings in patients with Parkinson's disease. *Neurol Sci* 39(3):533–541. <https://doi.org/10.1007/s10072-018-3244-2>
118. Uchida A, Pillai JA, Bermel R et al (2018) Visual neuroscience outer retinal assessment using spectral-domain optical coherence tomography in patients with alzheimer's and parkinson's disease. *Invest Ophthalmol Vis Sci* 7(59):2768–2777
119. Uchida A, Pillai JA, Bermel R et al (2020) Correlation between brain volume and retinal photoreceptor outer segment volume in normal aging and neurodegenerative diseases. *PLoS ONE* 15(9):e0237078. <https://doi.org/10.1371/journal.pone.0237078>
120. Mailankody P, Battu R, Khanna A, Lenka A, Yadav R, Pal PK (2015) Optical coherence tomography as a tool to evaluate retinal changes in Parkinson's disease. *Parkinsonism Relat Disord* 21(10):1164–1169. <https://doi.org/10.1016/j.parkreldis.2015.08.002>
121. Chorostecki J, Seraji-Bozorgzad N, Shah A et al (2015) Characterization of retinal architecture in Parkinson's disease. *J Neurol Sci* 355(1–2):44–48. <https://doi.org/10.1016/j.jns.2015.05.007>
122. Müller AK, Blasberg C, Südmeyer M, Aktas O, Albrecht P (2014) Photoreceptor layer thinning in parkinsonian syndromes. *Mov Disord* 29(9):1222–1223. <https://doi.org/10.1002/mds.25939>
123. Garcia-Martin E, Larrosa JM, Polo V et al (2014) Distribution of retinal layer atrophy in patients with parkinson disease and association with disease severity and duration. *Am J Ophthalmol* 157(2):470–478. <https://doi.org/10.1016/j.ajo.2013.09.028>
124. Roth NM, Saidha S, Zimmermann H et al (2014) Photoreceptor layer thinning in idiopathic Parkinson's disease. *Mov Disord* 29(9):1163–1170. <https://doi.org/10.1002/mds.25896>
125. Schneider M, Müller HP, Lauda F et al (2014) Retinal single-layer analysis in Parkinsonian syndromes: An optical coherence tomography study. *J Neural Transm* 121(1):41–47. <https://doi.org/10.1007/s00702-013-1072-3>
126. Lee JY, Kim JM, Ahn J, Kim HJ, Jeon BS, Kim TW (2014) Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's Disease. *Mov Disord* 29(1):61–67. <https://doi.org/10.1002/mds.25543>
127. Mailankody P, Battu R, Lenka A et al (2022) Retinal changes in parkinson's disease: a longitudinal follow-up study. *Neurol India* 70(3):1149–1153. <https://doi.org/10.4103/0028-3886.349658>
128. Oberwahrenbrock T, Weinhold M, Mikolajczak J et al (2015) Reliability of intra-retinal layer thickness estimates. *PLoS ONE* 10(9):e0137316. <https://doi.org/10.1371/journal.pone.0137316>
129. Nam KT, Yun C, Seo M, Ahn S, Oh J (2024) Comparison of retinal thickness measurements among four different optical coherence tomography devices. *Sci Rep* 14(1):3560. <https://doi.org/10.1038/s41598-024-54109-6>
130. Zhang Y, Yang L, Gao Y et al (2022) Choroid and choriocapillaris changes in early-stage Parkinson's disease: a swept-source optical coherence tomography angiography-based cross-sectional study. *Alzheimers Res Ther* 14(1):116. <https://doi.org/10.1186/s13195-022-01054-z>
131. Lujan BJ, Roorda A, Knighton RW, Carroll J (2011) Revealing Henle's fiber layer using spectral-domain optical coherence tomography. *Invest Ophthalmol Vis Sci* 52(3):1486–1492. <https://doi.org/10.1167/iovs.10-5946>
132. Gao W, Cense B, Zhang Y, Jonnal RS, Miller DT (2008) Measuring retinal contributions to the optical Stiles-Crawford effect with optical coherence tomography. *Opt Express* 16(9):6486–6501. <https://doi.org/10.1364/OE.16.006486>
133. Lujan BJ, Griffin SM, Makhijani VS et al (2024) DIRECTIONAL OPTICAL COHERENCE TOMOGRAPHY IMAGING OF MACULAR PATHOLOGY. *Retina* 44(7):1124–1133. <https://doi.org/10.1097/IAE.0000000000004105>
134. Tong KK, Lujan BJ, Zhou Y, Lin MC (2016) Directional optical coherence tomography reveals reliable outer nuclear layer measurements. *Optom Vis Sci* 93(7):714–719. <https://doi.org/10.1097/OPX.0000000000000861>
135. Lujan BJ, Roorda A, Croskrey JA et al (2015) DIRECTIONAL OPTICAL COHERENCE TOMOGRAPHY PROVIDES ACCURATE OUTER NUCLEAR LAYER AND HENLE FIBER LAYER MEASUREMENTS. *Retina* 35(8):1511–1520. <https://doi.org/10.1097/IAE.0000000000000527>
136. Gaire BP, Koronyo Y, Fuchs DT et al (2024) Alzheimer's disease pathophysiology in the Retina. *Prog Retin Eye Res* 101:101273. <https://doi.org/10.1016/j.preteyeres.2024.101273>
137. Snyder PJ, Alber J, Alt C et al (2021) Retinal imaging in Alzheimer's and neurodegenerative diseases. *Alzheimer's Dement* 17(1):103–111. <https://doi.org/10.1002/alz.12179>
138. Hood DC, La Bruna S, Tsamis E et al (2022) Detecting glaucoma with only OCT: Implications for the clinic, research, screening,

- and AI development. *Prog Retin Eye Res* 90:101052. <https://doi.org/10.1016/j.preteyeres.2022.101052>
139. Tran KKN, Wong VHY, Hoang A, Finkelstein DI, Bui BV, Nguyen CTO (2023) Retinal alpha-synuclein accumulation correlates with retinal dysfunction and structural thinning in the A53T mouse model of Parkinson's disease. *Front Neurosci* 17:1146979. <https://doi.org/10.3389/fnins.2023.1146979>
140. Tran KKN, Wong VHY, Lim JKH et al (2022) Characterization of retinal function and structure in the MPTP murine model of Parkinson's disease. *Sci Rep* 12(1):7610. <https://doi.org/10.1038/s41598-022-11495-z>